Abstract
Hemostasis is a preventative mechanism for blood loss after vessel injury, while thrombosis describes the pathogenic formation of thrombi. The precise balance of procoagulant and anticoagulant mechanisms keeps blood in a fluid state while circulating, yet can rapidly respond to vascular injury through clot formation. The initial formation of the platelet plug is classically termed “primary hemostasis,” while propagation of the coagulation cascade is termed “secondary hemostasis.”
After vessel injury, platelets adhere to the exposed subendothelium via von Willebrand factor and glycoprotein (GP) Ib-IX-V on the platelet surface. Platelets become activated and secrete a number of molecules including ADP and thromboxane A2, which are platelet agonists themselves leading to further platelet activation. Platelet recruitment and aggregation occurs through binding of platelet GPIIbIIIa receptors to fibrinogen leading to formation of the platelet plug. Tissue factor (TF) in the exposed subendothelium also binds to factor VIIa with formation of the TF-FVIIa complex. The TF-FVIIa complex initiates the coagulation cascade with the ultimate production of thrombin, which is a potent agonist for platelet activation.
Chronic atherosclerotic lesions are associated with plaque formation, which, when ruptured, exposes blood to collagen and to TF in the macrophages of atheroma. There are distinct hemostatic factors in the platelet and coagulation systems that modulate atherosclerosis and have an effect on atherothrombosis. A systemic inflammatory environment leads to a proatherogenic endothelium, independent of vessel wall injury. Atherogenic mediators include cytokines, adhesion molecules like P-selectin, and TF.
Given our thorough understanding of primary and secondary hemostasis, numerous antiplatelet and anticoagulant drugs have been synthesized. This chapter reviews in detail the mechanism of action and properties of the various agents used in clinical practice and some newer experimental agents.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Arnold DM, Rao AK. Disorders of platelet number and function. In: Gregory SA, McCrae KR, editors. American Society of Hematology self-assessment program. 4th ed. Washington, D.C.: Cadmus Communications Corporation; 2010. p. 241–62.
Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31:381–92.
Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28:403–12.
Brass LF. Thrombin and platelet activation. Chest. 2003;124:18S–25.
Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.
Mann KG. Thrombin formation. Chest. 2003;124:4S–10.
Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800–14.
Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248–57.
Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.
Dahlback B. Blood coagulation. Lancet. 2000;355:1627–32.
Maas C, Oschatz C, Thomas R. The plasma contact system 20. Semin Thromb Hemost. 2011;37:375–81.
Crawley JTB, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233–42.
Gebbink MF. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost. 2011;9 Suppl 1:174–81.
Undas A, Ariens AS. Fibrin clot structure and function A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31:e88–99.
Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364:1746–60.
Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:2507–13.
Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e89S–119.
Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32:2922–32.
Weitz DS, Weitz JI. Update on heparin: what do we need to know? J Thromb Thrombolysis. 2010;29:199–207.
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–88.
Abraham ME, Marcy TR. Warfarin versus dabigatran: comparing the old with the new. Consult Pharm. 2012;27:121–4.
Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12(Suppl F):27F–32.
Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581–92.
Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504–14.
Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20.
Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute st-segment elevation myocardial infarction: American College of Chest Physicians evidenced-based clinical practice guidelines (8th edition). Chest. 2008;133:708S–75.
Recommended Reading
Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.
Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.
Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20.
Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581–92.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bacchus, F.R., Crowther, M. (2013). Thrombosis. In: Rosendorff, C. (eds) Essential Cardiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6705-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6705-2_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6704-5
Online ISBN: 978-1-4614-6705-2
eBook Packages: MedicineMedicine (R0)